Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Children: An Analysis of 31 Cases

Haijin LI; Zhengcheng DUAN; Yan ZHOU; Liufang WANG; Chunhui YANG; Xin TIAN

doi:10.12259/j.issn.2095-610X.S20231215

Volume 44 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(12): 95-99

Haijin LI, Zhengcheng DUAN, Yan ZHOU, Liufang WANG, Chunhui YANG, Xin TIAN. Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Children: An Analysis of 31 Cases[J]. Journal of Kunming Medical University, 2023, 44(12): 95-99. doi: 10.12259/j.issn.2095-610X.S20231215

Citation:

Haijin LI, Zhengcheng DUAN, Yan ZHOU, Liufang WANG, Chunhui YANG, Xin TIAN. Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Children: An Analysis of 31 Cases[J]. Journal of Kunming Medical University, 2023, 44(12): 95-99. doi: 10.12259/j.issn.2095-610X.S20231215

Citation:

Haijin LI, Zhengcheng DUAN, Yan ZHOU, Liufang WANG, Chunhui YANG, Xin TIAN. Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Children: An Analysis of 31 Cases[J]. Journal of Kunming Medical University, 2023, 44(12): 95-99. doi: 10.12259/j.issn.2095-610X.S20231215

PDF( 586 KB)

Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Children: An Analysis of 31 Cases

doi: 10.12259/j.issn.2095-610X.S20231215

Dept. of Hematology and Oncology，Kunming Children’s Hospital/Children’s Hospital Affiliated to Kunming Medical University，Kunming Yunnan 650228，China

Received Date: 2023-09-19
Available Online: 2023-12-20
Publish Date: 2023-12-25

Abstract

Abstract

Objective To analyze the clinical characteristics of pediatric Langerhans cell histiocytosis（LCH）, and to analyse the expression characteristics and prognosis of BRAF-V600E mutation in LCH. Methods The clinical data of 31 children with LCH admitted to the Department of Hematology, Kunming Children's Hospital from February 2017 to December 2021 were retrospectively analyzed. Reference to LCH Shanghai children’ s medical center - 2011 revision chemotherapy（SCMC - LCH - 2011）, at the same time BRAF mutation - V600E targeted biopsies was treated by Dabrafenib. The clinical features, BRAF-V600E mutation and treatment response between single system LCH（SS-LCH） and multisystem LCH（MS-LCH） were summarized. The Kaplan-Meier method was used to draw the survival curve, and the Log-Rank test was used to compare the survival rate between groups. The Shanghai Children's Medical Center LCH-2011 revised chemotherapy regimen（SCMC-LCH-2011 regimen） was referenced, and the targeted drug Dabrafenib was added to treat those with the BRAF-V600E mutation. The clinical characteristics, BRAF-V600E mutation status, and treatment response between the single-system LCH（SS-LCH） group and the multisystem LCH（MS-LCH） group were summarized. Survival curves were plotted using the Kaplan-Meier method, and the Log-Rank test was used to compare the survival rates between the two groups. Results This study included a total of 31 cases, with 18 males and 13 females. The median age of onset was 10 months（ranging from 1 to 84 months）. 9 cases were SS-LCH, and 22 cases were MS-LCH, with 5 cases experiencing pituitary involvement/diabetes insipidus. Among the 27 cases that underwent BRAF-V600E mutation testing, 20 were positive（3 cases in the SS-LCH group, with a positivity rate of 37.5%; 17 cases in the MS-LCH group, with a positivity rate of 89.5%）. The difference in the BRAF-V600E mutation positivity rate between the two groups was statistically significant（P = 0.011）. The median follow-up time was 24 months（ranging from 3 to 62 months）. The effective rate after 6 weeks of induction chemotherapy was 88.9% in the SS-LCH group（8/9） and 81.8% in the MS-LCH group（18/22）. The observed progression-free rate at the end of the observation period reached 29.0%（9/31）. All three deaths occurred in the MS-LCH group with involvement of high-risk organs. There was no statistically significant difference in the overall survival rate between the SS-LCH and MS-LCH groups, as well as between the BRAF-V600E mutation positive and negative groups（χ² = 1.156, 0.437; P = 0.282, 0.508）. Conclusion LCH in children is more common in infants and young children, with a high incidence of BRAF-V600E gene mutation in affected children, and is often seen in MS-LCH. Dabrafenib may help improve the prognosis of children with BRAF-V600E mutation.
- Langerhans cell histiocytosis,
- Child,
- BRAF-V600E gene

FullText(HTML)

References(20)

References

[1]	Rollins B J. Genomic alterations in langerhans cell histiocytosis[J]. Hematology/Oncology Clinics of North America,2015,29(5):839-851. doi: 10.1016/j.hoc.2015.06.004
[2]	方凯弘,徐倩玥,余红. 儿童朗格汉斯细胞组织细胞增生症病因和治疗进展[J]. 临床儿科杂志,2019,37(3):228-232.
[3]	Allen C E,Merad M,Mcclain K L. Langerhans-cell histiocytosis[J]. The New England Journal of Medicine,2018,379(9):856-868. doi: 10.1056/NEJMra1607548
[4]	吴升华. 郎格罕细胞组织细胞增生症评估与治疗指南介绍[J]. 中华儿科杂志,2012, 50(2):155-158. doi: 10.3760/cma.j.issn.0578-1310.2012.02.016
[5]	Allen C E,Rodriguez-Galindo C. Langerhans cell histiocytosis[J]. Blood,2020,135(16):1319-1331. doi: 10.1182/blood.2019000934
[6]	Krooks J,Minkov M,Weatherall A G. Langerhans cell histiocytosis in ch-ildren history,classification,pathobiology,clinical manifestations,and prognosis[J]. Journal of the American Academy of Dermatology,2018,78(6):1035-1044. doi: 10.1016/j.jaad.2017.05.059
[7]	Leung A,Lam J M,Leong K F. Childhood Langerhans cell histiocytosis: A disease with many faces[J]. World J Pediatr,2019,15(6):536-545. doi: 10.1007/s12519-019-00304-9
[8]	王颖超,李壮壮,殷楚云,等. 伴口腔颌面部受累的朗格罕细胞组织细胞增生症12例临床分析[J]. 中国当代儿科杂志,2019,21(5):415-420.
[9]	廉红云,张莉,李志刚,等. 儿童颅面骨受累的朗格罕细胞组织细胞增生症临床分析[J]. 中华实用儿科临床杂志,2019,34(15):1151-1155. doi: 10.3760/cma.j.issn.2095-428X.2019.15.007
[10]	Zeng K,Ohshima K,Liu Y,et al. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children[J]. Hematologi-cal Oncology,2017,35(4):845-851. doi: 10.1002/hon.2344
[11]	Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy[J]. Expert Opin Pharmacother,2018,19(3):233-242. doi: 10.1080/14656566.2018.1429405
[12]	Héritier S,Emile J,Barkaoui M,et al. BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy[J]. Journal of Clinical Oncology,2016,34(25):3023-3030. doi: 10.1200/JCO.2015.65.9508
[13]	唐雪,郭霞,孙林雍,等. 儿童朗格汉斯细胞组织细胞增生症的BRAF-V600E基因突变及临床意义[J]. 中国当代儿科杂志,2018,20(4):290-294.
[14]	李建红,李萍,唐鹏跃,等. 儿童朗格汉斯细胞组织细胞增生症20例临床分析[J]. 中国皮肤性病学杂志,2018,32(6):650-653. doi: 10.13735/j.cjdv.1001-7089.201708051
[15]	冯楚础,黎阳,彭晓敏,等. 儿童朗格汉斯细胞组织细胞增生症临床特征与BRAF V600E基因突变的相关性分析[J]. 中华实用儿科临床杂志,2021,36(11):848-852.
[16]	Héritier S,Barkaoui M,Miron J,et al. Incidence and risk factors for clinical neurodegenerative langerhans cell histiocytosis: A longitudinal cohort study[J]. British Journal of Haematology,2018,183(4):608-617. doi: 10.1111/bjh.15577
[17]	Berres M,Lim K P H,Peters T,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups[J]. Journal of Experimental Medicine,2014,211(4):669-683. doi: 10.1084/jem.20130977
[18]	Donadieu J,Larabi I A,Tardieu M,et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: An international observational study[J]. J Clin Oncol,2019,37(31):2857-2865. doi: 10.1200/JCO.19.00456
[19]	Hazim A Z,Ruan G J,Ravindran A,et al. Efficacy of BRAF-inhibitor therapy in BRAF(V600E)-mutated adult langerhans cell histiocytosis[J]. Oncologist,2020,25(12):1001-1004. doi: 10.1002/onco.13541
[20]	Yang Y,Wang D,Cui L,et al. Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated langerhans cell histiocytosis[J]. Cancer Res Treat,2021,53(1):261-269. doi: 10.4143/crt.2020.769

Relative Articles(20)

Relative Articles

[1]	Ji WANG, Songtao BIN, Li TAN. Study on the Efficacy of Acetylcysteine in Severe Pneumonia in Children under Electronic Bronchoscopy. Journal of Kunming Medical University, 2024, 45(6): 113-119. doi: 10.12259/j.issn.2095-610X.S20240615
[2]	Wei HU, Jinnan LI, Wei YANG, Li SU, Zhuo YU, Zhisong CHEN. Interventional Treatment of Muscular Ventricular Septal Defect in Children. Journal of Kunming Medical University, 2024, 45(3): 48-53. doi: 10.12259/j.issn.2095-610X.S20240307
[3]	Haijin LI, Huiyuan LI, Xinmiao LIU, Yue TIAN, Na LI, Zhengcheng DUAN, Xin TIAN. Clinical Features and Prognosiss of Pediatric Acute Lymphoblastic Leukemia with Hyperleukocytosis. Journal of Kunming Medical University, 2024, 45(7): 105-112. doi: 10.12259/j.issn.2095-610X.S20240716
[4]	Xingzhu LIU, Yanfei YANG, Xing ZHANG, Liping GE, Feng WANG, Yuqin WU. Analysis of Lipid Metabolism Levels and Related Factors in Children with Kawasaki Disease in Different Courses. Journal of Kunming Medical University, 2023, 44(2): 113-119. doi: 10.12259/j.issn.2095-610X.S20230211
[5]	Jihua CUI, Shujin LI, Yu SONG, Yanfei YANG, Yanhui SUN, Jingjing SUN, Yu LING. The Predictive Value of Temperament in Children with Attention Deficit Hyperactivity Disorder. Journal of Kunming Medical University, 2023, 44(5): 125-131. doi: 10.12259/j.issn.2095-610X.S20230518
[6]	Yaling ZHAO, Kun WU, Rong HUANG, Genya HE, Zhenbo DING, Caiying ZHANG. Establishment and Significance of Screening System for Acute Leukemia in Children Based on Detection of TEL-AML1 Fusion Gene in Neonatal Cord Blood. Journal of Kunming Medical University, 2023, 44(1): 54-58. doi: 10.12259/j.issn.2095-610X.S20230126
[7]	Ying ZHANG, Hong GAO, Cuixiang ZHANG, Zeying CHEN, Hongqun ZOU, Liqiong LI, Jupin YANG, Yuexin HU. Helicobacter Pylori Infection in Children and its Correlation with Iron Deficiency Anemia. Journal of Kunming Medical University, 2022, 43(4): 103-106. doi: 10.12259/j.issn.2095-610X.S20220418
[8]	Haifeng MA, Kuiming JIANG. Value of 3.0T Magnetic Resonance Cholangiopancreatography in Diagnosing Pancreaticobiliary Maljunction in Children. Journal of Kunming Medical University, 2022, 43(10): 110-114. doi: 10.12259/j.issn.2095-610X.S20221014
[9]	Xian BAI, Yao CUI, Qing ZHOU, Xiaoli LI, Yuexiao LI, Juan LIU, Shinan ZHANG. Salivary Microbial Profiles of Dental Caries among Lisu Preschool Children in Yunnan Province. Journal of Kunming Medical University, 2022, 43(3): 86-93. doi: 10.12259/j.issn.2095-610X.S20220301
[10]	Song-tao BIN, Ming LI, Li TAN, Cheng-qing WU, Ji WANG, Xiao-qin HU. Clinical Analysis of 46 Children with Necrotizing Pneumonia. Journal of Kunming Medical University, 2021, 42(1): 124-129. doi: 10.12259/j.issn.2095-610X.S20210102
[11]	Shu-lan SHI, Xi-ting DAI, Guang-zhou ZHAO, Xiao Juan LI, Rong-jie LI, Ming-biao MA. Application of 16SrRNA Gene Detection in the Early Diagnosis of Bacterial Meningitis in Children. Journal of Kunming Medical University, 2021, 42(5): 120-125. doi: 10.12259/j.issn.2095-610X.S20210522
[12]	Sun Jian Ming , Dong Fang . Adverse Reactions in Children with Acute Lymphoblastic Leukemia after Chemotherapy. Journal of Kunming Medical University, 2017, 38(10): 107-111.
[13]	Qiu Wei , Chen Ying , Hu Xiu , Zhao Hong Yu . Analysis on Current Situation and Influencing Factors of Lead Poisoning in Children and Adolescents in Certain Region of Yunnan. Journal of Kunming Medical University, 2016, 37(11): 18-22.
[14]	Dai Mei . Risk Factors for Asthma in Children in Kunming City， China. Journal of Kunming Medical University,
[15]	Yang Shao Ling . . Journal of Kunming Medical University,
[16]	Wang Kun . . Journal of Kunming Medical University,
[17]	Bai Zhi Yao . . Journal of Kunming Medical University,
[18]	Sheng Xiao Cui . . Journal of Kunming Medical University,
[19]	He Li Yun . . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,